Rating History for Biohaven Pharma (BHVN) by Goldman Sachs
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/6/2026 | Corinne Johnson | New Coverage | Buy (N/A) |
23.00 (N/A) |
10.99 (9.92) |
-9.74% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/6/2026 | Corinne Johnson | New Coverage | Buy (N/A) |
23.00 (N/A) |
10.99 (9.92) |
-9.74% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||